Novel Drug Builds Bone in Postmenopausal Osteoporotic Women

Two words - Anabolic Clinic (sm).

No need for "novel drugs."

The investigational agent odanacatib appears to be an effective treatment for postmenopausal osteoporosis that persists after 3 years of alendronate therapy, according to a phase 3 trial presented here at ACR 2012.

Treatment with odanacatib significantly improved bone mineral density (BMD) at the femoral neck, hip, trochanter, and lumbar spine, compared with placebo, in postmenopausal women previously treated with alendronate.

The ones that used to work, still work.

And they work well.

To find out more, go here, here, and here.